Table 1 Baseline characteristics
All patients | Phase 2 dose | |
|---|---|---|
(N = 48) | (N = 45) | |
Age: Median (Range) | 64.5 (41.0–88.0) | 64.0 (41.0–88.0) |
Gender: Male | 25 (52.1%) | 24 (53.3%) |
ECOG performance score | ||
0 | 25 (52.1%) | 23 (51.1%) |
1 | 19 (39.6%) | 18 (40.0%) |
2 | 4 (8.3%) | 4 (8.9%) |
mSMART risk | ||
Standard risk | 34 (70.8%) | 31 (68.9%) |
High or intermediate | 14 (29.2%) | 14 (31.1%) |
Abnormal metaphase cytogenetics | 12 (25.0%) | 12 (26.7%) |
RISS | ||
Stage 1 | 15 (34.1%) | 14 (34.1%) |
Stage 2 | 27 (61.4%) | 25 (61.0%) |
Stage 3 | 2 (4.5%) | 2 (4.9%) |
Patients with stem cells collected | 28 (58.4%) | 28 (62.2%) |
